Alcon Inc. ALC gains on strong market share gains. The company’s broad pipeline and focus on research and innovation are impressive. Yet, a challenging international market with geopolitical ...

Alcon is a global leader in IOLs and controls 40%-50% of the market, by our estimate. Its AcrySof IQ IOL, which was launched in 1994, is most implanted IOL in the world. It was the first IOL to be ...

Alcon Research LLC is trying to engineer a cheap acquisition of Aurion Biotech Inc. by blocking Aurion’s other funding options and improperly gaining influence on its board, Aurion investors claim in ...

As Alcon Research seeks to block investee Aurion Biotech from listing on the New York Stock Exchange, another investor has come to Aurion’s defense. Deerfield Management has sued Alcon Research ...

Voyager Direct Selective Laser Trabeculoplasty (DSLT) will be launched at the American Glaucoma Society annual meeting in Washington, D.C. "I have been using Voyager DSLT since October of 2024 ...

3 “Alcon is dedicated to developing treatments and technologies for people living with glaucoma,” said Terry Kim, MD, Chief Medical Officer and Head of Global Medical Safety, Alcon. “By introducing ...

Alcon is a global leader in IOLs and controls 40%-50% of the market, by our estimate. Its AcrySof IQ IOL, which was launched in 1994, has been implanted in more than 135 million eyes, making it ...

53 LR Regulatory News: Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter ...

AcrySof Toric, Alcon Laboratories, Inc.). The current version of the Alcon toric calculator provides the surgeon a lens recommendation that is based on avoiding any overcorrection, as patients are ...